147 related articles for article (PubMed ID: 36723772)
1. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.
Tang V; Lu R; Mirchia K; Van Ziffle J; Devine P; Lee J; Phillips JJ; Perry A; Raleigh DR; Lucas CG; Solomon DA
Acta Neuropathol; 2023 Apr; 145(4):497-500. PubMed ID: 36723772
[No Abstract] [Full Text] [Related]
2. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Sievers P; Hielscher T; Schrimpf D; Stichel D; Reuss DE; Berghoff AS; Neidert MC; Wirsching HG; Mawrin C; Ketter R; Paulus W; Reifenberger G; Lamszus K; Westphal M; Etminan N; Ratliff M; Herold-Mende C; Pfister SM; Jones DTW; Weller M; Harter PN; Wick W; Preusser M; von Deimling A; Sahm F
Acta Neuropathol; 2020 Sep; 140(3):409-413. PubMed ID: 32642869
[No Abstract] [Full Text] [Related]
3. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
Wang JZ; Patil V; Liu J; Dogan H; Tabatabai G; Yefet LS; Behling F; Hoffman E; Bunda S; Yakubov R; Kaloti R; Brandner S; Gao A; Cohen-Gadol A; Barnholtz-Sloan J; Skardelly M; Tatagiba M; Raleigh DR; Sahm F; Boutros PC; Aldape K; ; Nassiri F; Zadeh G
Acta Neuropathol; 2023 Jul; 146(1):145-162. PubMed ID: 37093270
[TBL] [Abstract][Full Text] [Related]
4. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
5. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
6. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
[TBL] [Abstract][Full Text] [Related]
7. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
[TBL] [Abstract][Full Text] [Related]
8. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
[TBL] [Abstract][Full Text] [Related]
10. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
[TBL] [Abstract][Full Text] [Related]
11. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
Khan AB; English CW; Chen WC; Athukuri P; Bayley JC; Brandt VL; Shetty A; Hadley CC; Choudhury A; Lu HC; Harmanci AO; Harmanci AS; Magill ST; Raleigh DR; Klisch TJ; Patel AJ
Acta Neuropathol; 2023 Apr; 145(4):501-503. PubMed ID: 36729132
[No Abstract] [Full Text] [Related]
12. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
[TBL] [Abstract][Full Text] [Related]
14. [Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas].
Chen MN; Mao Q; Liu YH; Mao BY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Jun; 21(3):277-9. PubMed ID: 15192837
[TBL] [Abstract][Full Text] [Related]
15. Loss of p16
Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
[TBL] [Abstract][Full Text] [Related]
16. P16 deletion and mutation analysis in human brain tumors.
Barker FG; Chen P; Furman F; Aldape KD; Edwards MS; Israel MA
J Neurooncol; 1997 Jan; 31(1-2):17-23. PubMed ID: 9049826
[TBL] [Abstract][Full Text] [Related]
17. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
Tajima S; Koda K
Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas.
Ono Y; Ueki K; Joseph JT; Louis DN
Acta Neuropathol; 1996; 91(3):221-5. PubMed ID: 8834533
[TBL] [Abstract][Full Text] [Related]
19. Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre.
Marshall K; Jackson S; Jones J; Holme J; Lyons J; Barrett E; Taylor P; Bishop P; Hodgson C; Green M; Telford N; Evison M
Lung Cancer; 2020 Dec; 150():195-200. PubMed ID: 33197684
[TBL] [Abstract][Full Text] [Related]
20. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
